Olivier Ramuz

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi "Sugar" tumor of the pancreas: a rare entity that is diagnosable on preoperative fine-needle biopsies
    Olivier Ramuz
    Department of Pathology, Institut Paoli Calmettes, Marseille, France
    Virchows Arch 446:555-9. 2005
  2. ncbi Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas
    Olivier Ramuz
    Department of Pathology, Institut Paoli Calmettes, BP 156, 13273 Marseille Cedex 9, France
    Int J Oncol 26:151-7. 2005
  3. pmc FGFR1 and WT1 are markers of human prostate cancer progression
    Elizabeth Devilard
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm et Institut Paoli Calmettes, Marseille, France
    BMC Cancer 6:272. 2006
  4. ncbi Characterization of Hodgkin's lymphoma-like undifferentiated carcinoma of the nasopharyngeal type as a particular UCNT subtype mimicking Hodgkin's lymphoma
    Emmanuelle Charafe-Jauffret
    Department of Pathology, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite, BP 156, F 13273 Marseille cedex 9, France
    Int J Oncol 23:97-103. 2003
  5. pmc Constitutive nuclear localization and initial cytoplasmic apoptotic activation of endogenous caspase-3 evidenced by confocal microscopy
    Olivier Ramuz
    INSERM U119, Service d Anatomie et Cytologie Pathologiques, Laboratoire d Immunologie des Tumeurs, Institut Paoli Calmettes, IFR 57 and Université de la Méditerranée, Marseille, France
    Int J Exp Pathol 84:75-81. 2003
  6. ncbi Preoperative systemic chemotherapy does not modify strategy of liver resection
    Mehdi Ouaissi
    Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Hepatogastroenterology 53:405-8. 2006
  7. ncbi [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers]
    Colette Charpin-Taranger
    Faculte de Medecine Secteur Nord, Service d Anatomie et Cytologie Pathologiques, Boulevard Pierre Dramard Marseille, France
    Bull Acad Natl Med 187:1129-45; discussion 1145-6. 2003
  8. ncbi CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients
    Jean Philippe Dales
    Am J Clin Pathol 119:374-80. 2003
  9. ncbi Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome
    Jean Philippe Dales
    Service d Anatomie et de Cytologie Pathologiques, Hopital Nord, 13915 Marseille Cedex 20, France
    Int J Oncol 24:1197-204. 2004
  10. ncbi [Accuracy of intraoperative frozen section diagnosis in non palpable breast lesions: a series of 791 cases]
    Maryline Dorel-LeTheo
    Service d Anatomie et Cytologie Pathologiques, Hopital Nord, Chemin des Bourrelly, 13915 Marseille Cedex 20
    Bull Cancer 90:357-62. 2003

Collaborators

Detail Information

Publications11

  1. ncbi "Sugar" tumor of the pancreas: a rare entity that is diagnosable on preoperative fine-needle biopsies
    Olivier Ramuz
    Department of Pathology, Institut Paoli Calmettes, Marseille, France
    Virchows Arch 446:555-9. 2005
    ..This observation highlights that STs should be considered in preoperative differential diagnosis of pancreas tumors, since they may be treated by limited surgical resection...
  2. ncbi Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas
    Olivier Ramuz
    Department of Pathology, Institut Paoli Calmettes, BP 156, 13273 Marseille Cedex 9, France
    Int J Oncol 26:151-7. 2005
    ..Our data suggest that TCL1A immunodetection is an independent marker of adverse outcome that could be used in routine settings for the management of DLCL patients...
  3. pmc FGFR1 and WT1 are markers of human prostate cancer progression
    Elizabeth Devilard
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm et Institut Paoli Calmettes, Marseille, France
    BMC Cancer 6:272. 2006
    ..Androgen-independent prostate adenocarcinomas are responsible for about 6% of overall cancer deaths in men...
  4. ncbi Characterization of Hodgkin's lymphoma-like undifferentiated carcinoma of the nasopharyngeal type as a particular UCNT subtype mimicking Hodgkin's lymphoma
    Emmanuelle Charafe-Jauffret
    Department of Pathology, Institut Paoli Calmettes, 232 Boulevard de Sainte Marguerite, BP 156, F 13273 Marseille cedex 9, France
    Int J Oncol 23:97-103. 2003
    ..These results show that UCNT morphologically resembling HL share also some specific phenotypical and molecular features with HL, and might deserve to be isolated as a particular UCNT subtype...
  5. pmc Constitutive nuclear localization and initial cytoplasmic apoptotic activation of endogenous caspase-3 evidenced by confocal microscopy
    Olivier Ramuz
    INSERM U119, Service d Anatomie et Cytologie Pathologiques, Laboratoire d Immunologie des Tumeurs, Institut Paoli Calmettes, IFR 57 and Université de la Méditerranée, Marseille, France
    Int J Exp Pathol 84:75-81. 2003
    ..These results provide new perspectives about the subcellular compartmentation and traffic of caspases during the apoptotic process...
  6. ncbi Preoperative systemic chemotherapy does not modify strategy of liver resection
    Mehdi Ouaissi
    Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Hepatogastroenterology 53:405-8. 2006
    ....
  7. ncbi [The immunohistochemical expression of CD105 is a marker for high metastatic risk and worse prognosis in breast cancers]
    Colette Charpin-Taranger
    Faculte de Medecine Secteur Nord, Service d Anatomie et Cytologie Pathologiques, Boulevard Pierre Dramard Marseille, France
    Bull Acad Natl Med 187:1129-45; discussion 1145-6. 2003
    ..Moreover, the CD105 immunodetection may also be considered as a potential tool for selecting patients that could benefit from specific antiangiogenic therapy, using anti CD105 conjugates...
  8. ncbi CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients
    Jean Philippe Dales
    Am J Clin Pathol 119:374-80. 2003
    ..Moreover, immunodetection of CD105 also may be considered a potential tool for selecting patients who could benefit from specific antiangiogenic therapy, using anti-CD105 conjugates...
  9. ncbi Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome
    Jean Philippe Dales
    Service d Anatomie et de Cytologie Pathologiques, Hopital Nord, 13915 Marseille Cedex 20, France
    Int J Oncol 24:1197-204. 2004
    ....
  10. ncbi [Accuracy of intraoperative frozen section diagnosis in non palpable breast lesions: a series of 791 cases]
    Maryline Dorel-LeTheo
    Service d Anatomie et Cytologie Pathologiques, Hopital Nord, Chemin des Bourrelly, 13915 Marseille Cedex 20
    Bull Cancer 90:357-62. 2003
    ....
  11. pmc Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma
    Maher K Gandhi
    Australian Centre for Vaccine Development, Tumor Immunology Laboratory, Division of Infectious Diseases and Immunology, Queensland Institute of Medical Research, Brisbane, Australia
    Blood 110:1326-9. 2007
    ..These observations provide an important link between the Gal-1-mediated immunomodulatory networks and loss of antigen-specific T-cell function in classic HL...